Get Started. It's Free
or sign up with your email address
Rocket clouds
Taxonomy by Mind Map: Taxonomy

1. Understanding PD (1.6, 2.2, 1.2.1 - Capture every Keyword in Grant database)

1.1. Suspected Causes ***

1.1.1. Idiopathic

1.1.2. Epidemiology

1.1.2.1. Environment

1.1.2.1.1. Pesticides

1.1.2.1.2. Solvents

1.1.2.1.3. Heavy Metals

1.1.2.1.4. Head Injury

1.1.2.1.5. Behavioural

1.1.2.2. Genetics

1.1.2.2.1. Alpha-Synuclein

1.1.2.2.2. Parkin

1.1.2.2.3. PARK3

1.1.2.2.4. UCH-L1

1.1.2.2.5. PINK1

1.1.2.2.6. DJ-1

1.1.2.2.7. LRRK2

1.1.2.2.8. Tau

1.1.2.2.9. GBA

1.1.2.2.10. ATP13A2

1.1.3. Pathophysiology

1.1.3.1. Estrogen

1.1.3.2. Excitotoxicity

1.1.3.3. Inflammation

1.1.3.4. Metals

1.1.3.4.1. Iron

1.1.3.4.2. Manganese

1.1.3.5. Trophic Factors ^^^^^

1.1.3.5.1. GDNF ^^^^

1.1.3.5.2. NTN

1.1.3.5.3. CDNF

1.1.3.5.4. BDNF

1.1.3.6. Antioxidant

1.1.3.6.1. Coenzyme Q10

1.1.3.7. Mitochondrial Dysfunction

1.1.3.8. Protein Handling

1.1.3.9. Neurodegeneration

1.2. PD Diagnosis

1.2.1. Biomarkers ^^^^^

1.2.1.1. Olfactory Dysfunction

1.2.1.1.1. Smell Test

1.2.1.2. Neuroimaging

1.2.1.2.1. Diffusion Tensor Imaging Scan

1.2.1.2.2. MRI

1.2.1.2.3. DatScan

1.2.1.2.4. PET Scan

1.2.1.2.5. Transcranial Doppler

1.2.1.2.6. SPECT Scan

1.2.1.3. Neuropathology

1.2.1.3.1. Lewy Bodies

1.2.2. Clinical Scales

1.2.2.1. UPDRS

1.2.3. Questions for Doctor ***

1.2.4. Prediagnosis

1.2.5. PD Subtypes

1.3. Symptoms & Side Effects

1.3.1. Motor Symptoms

1.3.1.1. Resting Tremor

1.3.1.2. Dexterity

1.3.1.3. Rigidity

1.3.1.4. Bradykinesia

1.3.1.5. Postural Instability and Gait Disorder

1.3.1.5.1. Freezing

1.3.1.5.2. Festination

1.3.1.5.3. Postural Instability (falling)

1.3.1.6. Motor Fluctuations

1.3.1.7. Dystonia

1.3.2. Non-Motor Symptoms

1.3.2.1. Parkinsons Mask

1.3.2.2. Cognitive Changes *** ^^^^^

1.3.2.2.1. Apathy

1.3.2.2.2. Depression ***

1.3.2.2.3. Psychosis ***

1.3.2.2.4. Anxiety ***

1.3.2.2.5. Neurobehavioral

1.3.2.2.6. Dementia

1.3.2.3. Dysphagia (swallowing)

1.3.2.4. Sialorrhea (excessive salivation)

1.3.2.5. Sleep Disorders ***

1.3.2.6. Fatigue

1.3.2.7. Speech Difficulties ***

1.3.2.8. Hallucinations

1.3.2.9. Autonomic Dysfunction

1.3.2.9.1. Orthostatic Hypotension (low blood pressure)

1.3.2.9.2. Sexual Health ***

1.3.2.9.3. Constipation/Bladder

1.3.2.10. Pain

1.3.3. Neuropharmacology

1.3.3.1. Nurr1

1.3.3.2. Glutamate Receptors

1.3.3.2.1. mGluR5

1.3.3.3. Serotonin receptors

1.3.3.4. Adenosine Receptors

1.3.3.5. Basal Ganglia

1.3.4. Complications of Treatment

1.3.4.1. Dyskinesia *** ^^^^^

1.3.4.2. Compulsions

1.3.4.2.1. Impulse Control

1.4. Treatment

1.4.1. Delivery

1.4.1.1. Oral

1.4.1.2. Surgical

1.4.1.3. Inhalant

1.4.1.4. Blood Brain Barrier

1.4.1.5. Subcutaneous

1.4.1.6. Transdermal (Patch)

1.4.1.7. Intraduodenal Infusion (Duodopa)

1.4.1.8. Gene Therapy

1.4.1.9. RNAi

1.4.2. Medications ***

1.4.2.1. Amantadine (Symmetrel

1.4.2.2. Apomorphine (Apokyn)

1.4.2.3. Benztropine (Cogentin)

1.4.2.4. Bromocriptine (Parlodel)

1.4.2.5. Carbidopa-levodopa (Sinemet)

1.4.2.6. Levodopa-benserazide (Madopar)

1.4.2.7. Pramipexole (Mirapex, Mirapex ER, Mirapexin, Sifrol)

1.4.2.8. Ropinirole (Adartel, Requip, Requip XL, Ropark)

1.4.2.9. Trihexyphenidyl (Apo-Trihex, Artane)

1.4.2.10. MAO-B Inhibitors

1.4.2.10.1. Selegiline (I-deprenyl, Eldepryl, Zelapar)

1.4.2.10.2. Rasagiline (Azilect)

1.4.2.11. COMT Inhibitors

1.4.2.11.1. Entacapone (Comtan)

1.4.2.11.2. Tolcapone (Tasmar)

1.4.2.11.3. Carbidopa, levodopa, and entacapone (Stalevo)

1.4.3. Non-Drug Treatment

1.4.3.1. DBS/Other Stimulation Interventions

1.4.3.2. Pallidotomy

1.4.3.3. Thalamotomy

1.4.4. Alternative Medicine

1.4.4.1. Acupuncture

1.4.4.2. Mucuna Pruens

1.4.5. Exercise

1.4.5.1. Physical Therapy

1.4.6. Placebo Response

1.4.7. Translational Stage

1.4.7.1. Discovery

1.4.7.2. Pre-Clinical

1.4.7.3. Clinical

1.4.7.3.1. Phase I Trial

1.4.7.3.2. Phase II Trial

1.4.7.3.3. Phase III Trial

1.4.7.3.4. Phase IV Trial

1.4.8. Treatment Goal

1.4.8.1. Neuroprotective/ Regenerative

1.4.8.1.1. Cell Replacement

1.5. Living With

1.5.1. Living Alone with PD

1.5.2. Staying Optimistic

1.5.3. Sharing Your Diagnosis with Loved Ones

1.5.4. Support Groups

1.5.5. Safety at Home

1.5.6. PD relation to other diseases

1.5.6.1. Alzheimers

1.5.6.2. Atypical Parkinsonisms

1.5.7. PD and Employment

1.5.8. Caring for Someone with PD

1.5.9. PD and Insurance

1.5.10. Nutrition

1.5.11. Driving

2. MJFF Activity (1.6 and 1.6.2 and 1.2.1)

2.1. Fox Trial Finder

2.1.1. FTF Newsletter

2.2. Parkinson's Progression Markers Initiative

2.2.1. PPMI Newsletter

2.3. Partners Program

2.4. Legacy Circle

2.5. Events

2.5.1. Foundation Events

2.5.1.1. Education

2.5.1.1.1. Research RoundTables

2.5.1.1.2. PD Therapeutics Conference

2.5.1.1.3. Hot Topics Calls

2.5.1.2. Fundraising

2.5.1.2.1. Funny Thing

2.5.1.2.2. Sunny Thing

2.5.1.2.3. Poker Tournament

2.5.2. Community Fundraising Events

2.5.2.1. Nonathletic

2.5.2.2. Athletic

2.5.2.2.1. Triatholon

2.5.2.2.2. Run

2.5.2.2.3. Ride

2.5.2.2.4. Walk/Hike

2.6. Research Grants

2.6.1. Pipeline Program

2.6.1.1. Target Validation

2.6.1.2. Theraputic Development

2.6.1.3. Repositioning

2.6.1.4. Rapid Response

2.6.1.5. Clinical Intervention Awards

2.6.2. Funding Priority Area

2.6.2.1. Research Tools ^^^^^

2.6.2.1.1. Pre-clinical models

2.6.2.1.2. Assays

2.7. Publications

2.7.1. News in Context

2.7.2. Case Studies

2.7.3. Newsletters

2.7.4. Annual Reports

2.7.5. Press Releases

2.8. Photo Gallery

2.9. Podcast

2.10. Video

2.10.1. Ask the MD

2.11. Seminar Series

2.12. Smarter Practices

2.12.1. Internet/New Media-based Initiatives

2.12.2. Data Sharing

3. Organizations (1.9) Version 2

3.1. Fundraising Partners

3.2. Program Partners

4. People (1.3 and 1.6 and Blog Audience)

4.1. Foundation

4.1.1. Board of Directors

4.1.2. Founder's Council

4.1.3. Leadership Council

4.1.4. Patient Council

4.1.5. Scientific Advisors

4.1.6. Foundation Staff

4.1.6.1. Leadership Staff

4.1.6.2. Research Programs

4.1.6.3. Research Operations

4.1.6.4. Research Partnerships

4.1.6.5. Advancement

4.1.6.6. Marketing & Communications

4.1.6.7. Digital Strategy

4.1.6.8. Administration

4.2. Michael J Fox

4.2.1. Actor

4.2.1.1. Good Wife

4.2.1.2. Back to the Future

4.2.2. Author

4.2.2.1. Lucky Man

4.2.3. Advocate

4.2.3.1. Awards

4.2.3.2. Speech

4.2.3.3. Honorary Degrees

4.3. Clinician

4.4. Parkinson's Orgs

4.4.1. PAN

4.4.2. Unity Walk

4.5. Parkinsons Patient

4.5.1. Newly Diagnosed Patient

4.5.2. Young Onset Patient

4.5.3. Late Stage Patient

4.6. Team Fox

4.6.1. Clinical Trial Participant

4.6.1.1. PPMI Participant

4.6.1.2. Control

4.6.2. Fundraiser

4.6.2.1. Team Fox Athlete

4.6.2.2. Team Fox Event Organizer

4.6.3. Donor

4.6.4. Team Fox Mentors

4.6.5. Team Fox Young Professionals

4.7. Industry

4.8. Researcher

4.9. Caregiver

4.10. Academia/Nonprofit

4.11. Industry/Nonprofit Collaboration

5. Geography (3.4 and 1.3 and 1.6)

5.1. Australia

5.2. South America

5.2.1. Brazil

5.2.2. Argentina

5.3. Asia

5.3.1. Japan

5.3.2. China

5.4. Europe

5.4.1. Denmark

5.4.2. Spain

5.4.3. Slovakia

5.4.4. United Kingdom

5.4.5. Turkey

5.4.6. Finland

5.4.7. France

5.4.8. Italy

5.4.9. Austria

5.4.10. Germany

5.4.11. Netherlands

5.4.12. Ireland

5.5. North America

5.5.1. Puerto Rico

5.5.2. Bermuda

5.5.3. United States

5.5.3.1. West

5.5.3.1.1. California

5.5.3.1.2. Colorado

5.5.3.1.3. Arizona

5.5.3.1.4. New Mexico

5.5.3.1.5. Utah

5.5.3.1.6. Nevada

5.5.3.1.7. Wyoming

5.5.3.1.8. Idaho

5.5.3.1.9. Montana

5.5.3.1.10. Washington

5.5.3.1.11. Oregon

5.5.3.1.12. Hawaii

5.5.3.1.13. Alaska

5.5.3.2. MidWest

5.5.3.2.1. North Dakota

5.5.3.2.2. South Dakota

5.5.3.2.3. Nebraska

5.5.3.2.4. Minnesota

5.5.3.2.5. Kansaasa

5.5.3.2.6. Oklahoma

5.5.3.2.7. Iowa

5.5.3.2.8. Missouri

5.5.3.2.9. Arkansas

5.5.3.2.10. Wisconsin

5.5.3.2.11. Michigan

5.5.3.2.12. Illinois

5.5.3.2.13. Indiana

5.5.3.2.14. Kentucky

5.5.3.2.15. Ohio

5.5.3.3. South

5.5.3.3.1. Georgia

5.5.3.3.2. Texas

5.5.3.3.3. Louisiana

5.5.3.3.4. Mississsippi

5.5.3.3.5. Tennessee

5.5.3.3.6. Alabama

5.5.3.3.7. South Carolina

5.5.3.3.8. North Carolina

5.5.3.3.9. Florida

5.5.3.4. MidAtlantic

5.5.3.4.1. New York

5.5.3.4.2. New Jersey

5.5.3.4.3. Pennsylvania

5.5.3.4.4. Delaware

5.5.3.4.5. Maryland

5.5.3.4.6. West Virginia

5.5.3.4.7. Virginia

5.5.3.4.8. Washington DC

5.5.3.5. New England

5.5.3.5.1. Maine

5.5.3.5.2. Vermont

5.5.3.5.3. New Hampshire

5.5.3.5.4. Massachussettes

5.5.3.5.5. Connecticut

5.5.3.5.6. Rhode Island

5.5.4. Mexico

5.5.5. Canada

5.6. Africa

5.6.1. South Africa